Show simple item record

dc.contributor.authorRitmeijer, Koert; Kumar Das, Asish; Ahmed, Be-Nazir; den Boer, Margriet; Almeida, Patrick; Verputten, Meggy*
dc.date.accessioned2014-06-23T15:06:32Z
dc.date.available2014-06-23T15:06:32Z
dc.date.issued2014-06
dc.identifier.urihttp://hdl.handle.net/10144/322173
dc.descriptionResearch protocol. These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen_GB
dc.description.abstractGeneral objective To evaluate the effectiveness and safety of PKDL treatment with AmBisome 15 mg/kg total dose, given over 15 days in 5 infusions (twice weekly) of 3mg/kg on an ambulatory basis in a primary health care setting. Primary objective: to evaluate the effectiveness of AmBisome 15 mg/kg total dose at 12 M Secondary objective: • Evaluate the safety of AmBisome 3mg/kg x 5 infusions (twice weekly) (15 mg/kg total dose) • Evaluate the occurrence of hypokalaemia • Evaluate at which point in time lesions start to respond to treatment.
dc.language.isoenen
dc.subjectPKDLen_GB
dc.subjectAmbisomeen_GB
dc.subjectvisceral leishmaniasisen_GB
dc.titleResearch Protocol - Post-kala-azar Dermal Leishmaniasis (PKDL): a prospective observational study of the effectiveness and safety of an ambulatory short course treatment with AmBisome* 15 mg/kg total doseen
dc.typeOtheren
dc.contributor.departmentMSF-Holland, Amsterdam, The Netherlands; MSF-Holland, Fulbaria, Bangladesh; CDC, (DGHS); MSF-Holland, Amsterdam, The Netherlands; MSF-Holland, Dhaka, Bangladesh; MSF-Holland, Amsterdam, The Netherlandsen_GB
refterms.dateFOA2019-02-21T13:45:54Z
html.description.abstractGeneral objective To evaluate the effectiveness and safety of PKDL treatment with AmBisome 15 mg/kg total dose, given over 15 days in 5 infusions (twice weekly) of 3mg/kg on an ambulatory basis in a primary health care setting. Primary objective: to evaluate the effectiveness of AmBisome 15 mg/kg total dose at 12 M Secondary objective: • Evaluate the safety of AmBisome 3mg/kg x 5 infusions (twice weekly) (15 mg/kg total dose) • Evaluate the occurrence of hypokalaemia • Evaluate at which point in time lesions start to respond to treatment.


Files in this item

Thumbnail
Name:
OCA013-14_Proposal PKDL 15 mgkg ...
Size:
82.99Kb
Format:
Microsoft Word 2007
Description:
Research Protocol

This item appears in the following Collection(s)

Show simple item record